What We Monitor for CROs
GCP inspection trends & findings
Clinical trial conduct guidance
IND/IDE submission expectations
Decentralized trial frameworks
Real-world evidence integration
Data integrity enforcement signals
Informed consent requirements
Safety reporting obligations
Electronic records (21 CFR Part 11)
Decisions This Intelligence Affects
Study Operations
- • Protocol design alignment with FDA expectations
- • Site selection and qualification criteria
- • Monitoring strategy adjustments
- • Decentralized trial implementation
Quality & Compliance
- • GCP compliance program priorities
- • Inspection readiness focus areas
- • CAPA process refinement
- • Vendor qualification standards
Regulatory Strategy
- • Sponsor advisory on pathway selection
- • Pre-IND/Pre-IDE meeting preparation
- • Endpoint selection guidance
- • Adaptive design considerations
Business Development
- • Therapeutic area capability positioning
- • Competitive differentiation on compliance
- • Sponsor relationship intelligence
- • Service offering expansion
How CROs Use This Intelligence
Anticipate GCP Enforcement Shifts
Detect inspection focus changes before sponsor audits
Advise Sponsors Proactively
Position your regulatory expertise with current FDA thinking
Reduce Compliance Research Time
Pre-interpreted guidance saves 10+ hours per major update
Strengthen Protocol Design
Align trial design with evolving FDA expectations
Differentiate on Compliance
Demonstrate regulatory awareness in sponsor proposals
Support Audit Readiness
Document regulatory rationale for inspection defense